M4MM

Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Operators sharpened their focus on balance sheets and strategic footholds while policymakers grappled with regulatory gaps and emerging threats. Funding flowed into psychedelics innovation, MSOs reported Q3 2025 earnings, trimmed underperformers, and ...

Cronos Group Reports Q3 2025 Financial Results

TORONTO – Cronos Group Inc., a Canadian Cannabis producer with a growing international footprint, reported third-quarter results that marked new highs for revenue, profitability, and cash reserves, even as domestic challenges in Canada tempered some ...

Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Operators sharpened their focus on balance sheets and strategic footholds while policymakers grappled with regulatory gaps and emerging threats. Funding flowed into psychedelics innovation, MSOs reported Q3 2025 earnings, trimmed underperformers, and ...

Cronos Group Reports Q3 2025 Financial Results

TORONTO – Cronos Group Inc., a Canadian Cannabis producer with a growing international footprint, reported third-quarter results that marked new highs for revenue, profitability, and cash reserves, even as domestic challenges in Canada tempered some ...

COMPASS Pathways Receives Analyst Ratings

LOS ANGELES- COMPASS Pathways, a company specializing in mental health treatments, has garnered significant attention in recent market reports due to favorable analyst ratings and its stock performance. Several brokerages have maintained a consensus "Buy" ...

Verano Holdings to Participate in Key Investor Conferences

LOS ANGELES- Verano Holdings Corp. U.S. multi-state cannabis company, has announced its participation in two significant industry conferences. The company’s executives will engage with investors and industry leaders to discuss important market developments and future ...

MindMed to Present at Key September Investor Conferences

LOS ANGELES- Mind Medicine (MindMed) Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders, announced its participation in three significant investor conferences in September 2024. MindMed’s management team will engage ...

Subscribe To Our Newsletter